Faculty profile

Rama Khokha

ResearcherCancer ResearchUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses may be missing. Find their university profile.

Rama Khokha

Researcher

Cancer Research

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
17 publications in the last five years, latest in 2026.
Senior (last) author on 5 recent papers, a sign of leading a research group.
Principal investigator on 8 research grants (8 CIHR), most recently in 2024.
Supervised 6 trainees who won CIHR awards, most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Breast Cancer Crc Biospecimen Repository Breast Cancer Prevention Cancer Precursors Cell Vulnerabilities Early Interception High-Risk Patients

Latest papers

Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target
Cell Reports Medicine · 2026
The histone lysine methyltransferase NSD3 drives osteosarcomagenesis by inactivating ARID3A.
Cancer letters · 2025 · senior author
Tumour tissue: heterogeneous, but not disordered.
Nature reviews. Cancer · 2025 · senior author

All 88 publications

Latest funding

Targeting breast involution for the primary prevention of breast cancer among women who inherit a pathogenic variant in breast cancer 1 (BRCA1)
CIHR · 2025 · Co-investigator
$998,395
Evaluating PARP inhibitors for primary breast cancer prevention
CIHR · 2024 · Nominated PI
$65,000
Canada Research Chair - Tier 1
CIHR · 2024 · Nominated PI
$1,400,000

All 16 grants and awards

88 publications.

Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target

Govindarajan M, Mejia-Guerrero S, Chafe SC, Khan S, Shi W, Waas M, Rossotti MA, Khoo A, Liu LY, Ignatchenko V

Cell Reports Medicine20262 citations

DOI: 10.1016/j.xcrm.2025.102578

The histone lysine methyltransferase NSD3 drives osteosarcomagenesis by inactivating ARID3A.

Lu J, Shao Y, Saw S, Fang H, Song G, Chen Y, Tang Q, Wood G, Wang J, Waterhouse P, Shen J, Khokha R

Cancer letters2025Senior author

DOI: 10.1016/j.canlet.2025.218045 PMID: 40967468

Tumour tissue: heterogeneous, but not disordered.

Grünwald BT, Khokha R

Nature reviews. Cancer2025Senior author

DOI: 10.1038/s41568-025-00852-5 PMID: 40659926

Anti-progestin therapy targets hallmarks of breast cancer risk.

Simões BM, Pedley R, McCloskey CW, Roberts M, Reed AD, Twigger AJ, Tharmapalan P, Caruso A, Cabral S, Wilby AJ, Harrison H, Zhou Y, Greenhalgh A, Alghamdi SA, Forestiero M, Lopez-Muñoz J, Roche J, Tuieng RJ, Khan MA, Squires S, Astley SM, Harkness EF, Santiago-Gómez A, Spence K, Ritchie J, Pritchard S, Lim Y, Sherratt MJ, Andò S, Howell A, Evans DG, Gilmore AP, Khaled WT, Khokha R, Clarke RB, Howell SJ

Nature2025

DOI: 10.1038/s41586-025-09684-7 PMID: 41193807

Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer.

Klein L, Tu M, Krebs N, Urbach L, Grimm D, Latif MU, Penz F, Blandau A, Wu X, Samuel RD, Küffer S, Wegwitz F, Chan N, Aliar K, Vyas F, Kishore U, Hessmann E, Trumpp A, Espinet E, Papantonis A, Khokha R, Ellenrieder V, Grünwald BT, Singh SK

Nature communications2025

DOI: 10.1038/s41467-024-55330-7 PMID: 39762215

A metabolic shift to the serine pathway induced by lipids fosters epigenetic reprogramming in nontransformed breast cells.

Eduardo MB, Cottone G, McCloskey CW, Liu S, Palma FR, Zappia MP, Islam ABMMK, Gao P, Setya J, Dennis S, Gao H, Zhang Q, Xuei X, Luo Y, Locasale J, Bonini MG, Khokha R, Frolov MV, Benevolenskaya EV, Chandel NS, Khan SA, Clare SE

Science advances2025

DOI: 10.1126/sciadv.ads9182 PMID: 40117373

Parity, breastfeeding, and the risk of early-onset breast cancer in women with a BRCA1 pathogenic variant

Kotsopoulos J, Maxwell CA, Lubinski J, Huzarski T, Kim RH, Tung N, Eisen A, Foulkes W, Aeilts A, Neuhausen SL

British Journal of Cancer20252 citations

DOI: 10.1038/s41416-025-03029-x

Dipeptidyl-peptidase 9 regulates the dynamics of tumorigenesis and metastasis in breast cancer.

Heß L, Aliar K, Grünwald BT, Griffin R, Lozan A, Knöller M, Khokha R, Brummer T, Reinheckel T

Biochimica et biophysica acta. Molecular basis of disease2024

DOI: 10.1016/j.bbadis.2024.167133 PMID: 38531482

Metalloproteinase inhibitors regulate biliary progenitor cells through sDLK1 in organoid models of liver injury.

Defamie V, Aliar K, Sarkar S, Vyas F, Shetty R, Reddy Narala S, Fang H, Saw S, Tharmapalan P, Sanchez O, Knox JJ, Waterhouse PD, Khokha R

The Journal of clinical investigation2024Senior author

DOI: 10.1172/jci164997 PMID: 39699962

Droplet-based proteomics reveals CD36 as a marker for progenitors in mammary basal epithelium.

Waas M, Khoo A, Tharmapalan P, McCloskey CW, Govindarajan M, Zhang B, Khan S, Waterhouse PD, Khokha R, Kislinger T

Cell reports methods2024

DOI: 10.1016/j.crmeth.2024.100741 PMID: 38569541

Something wrong or missing on this profile? Suggest a correction

Rama Khokha

Research

Latest papers

Latest funding

Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target

The histone lysine methyltransferase NSD3 drives osteosarcomagenesis by inactivating ARID3A.

Tumour tissue: heterogeneous, but not disordered.

Anti-progestin therapy targets hallmarks of breast cancer risk.

Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer.

A metabolic shift to the serine pathway induced by lipids fosters epigenetic reprogramming in nontransformed breast cells.

Parity, breastfeeding, and the risk of early-onset breast cancer in women with a BRCA1 pathogenic variant

Dipeptidyl-peptidase 9 regulates the dynamics of tumorigenesis and metastasis in breast cancer.

Metalloproteinase inhibitors regulate biliary progenitor cells through sDLK1 in organoid models of liver injury.

Droplet-based proteomics reveals CD36 as a marker for progenitors in mammary basal epithelium.

Frequent collaborators

Thomas Kislinger

Steven Gallinger

Faiyaz Notta

Mathieu Lupien

Ming-Sound Tsao

Vuk Stambolic

Chiara Gorrini

Marianne Koritzinsky

Daniel Schramek

Stefan Hofer

Laurie Ailles

Benjamin Haibe-Kains

Daniel De Carvalho

Wei Xu

Josef Penninger

Moulay Alaoui-Jamali

Peter Liu

Dalia Barsyte-Lovejoy

Robert Grant

Jagdish Butany

Osvaldo Espin Garcia

Pingzhao Hu

Cheryl Arrowsmith

Connie Eaves

Fei-Fei Liu

Andrea Eisen

Louise Bordeleau

Heather Reich

Andrea Eisen

Sheila Singh